company background image
AMTI

Applied Molecular TransportNasdaqGS:AMTI Stock Report

Market Cap

US$628.5m

7D

-23.9%

1Y

-50.5%

Updated

26 Nov, 2021

Data

Company Financials +
AMTI fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AMTI Stock Overview

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Applied Molecular Transport
Historical stock prices
Current Share PriceUS$16.33
52 Week HighUS$78.22
52 Week LowUS$15.89
Beta0
1 Month Change-25.94%
3 Month Change-47.32%
1 Year Change-50.47%
3 Year Changen/a
5 Year Changen/a
Change since IPO-9.18%

Recent News & Updates

Aug 29
We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

AMTIUS BiotechsUS Market
7D-23.9%0.4%-2.7%
1Y-50.5%5.3%21.3%

Return vs Industry: AMTI underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: AMTI underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is AMTI's price volatile compared to industry and market?
AMTI volatility
AMTI Average Weekly Movement7.0%
Biotechs Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: AMTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AMTI's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010113Tahir Mahmoodhttps://www.appliedmt.com

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects.

Applied Molecular Transport Fundamentals Summary

How do Applied Molecular Transport's earnings and revenue compare to its market cap?
AMTI fundamental statistics
Market CapUS$628.53m
Earnings (TTM)-US$89.16m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMTI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$33.66m
Gross Profit-US$33.66m
ExpensesUS$55.51m
Earnings-US$89.16m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.32
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AMTI perform over the long term?

See historical performance and comparison

Valuation

Is Applied Molecular Transport undervalued compared to its fair value and its price relative to the market?

3.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AMTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AMTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AMTI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AMTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMTI is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Applied Molecular Transport forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-7.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AMTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AMTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AMTI's revenue is forecast to grow faster than the US market.

High Growth Revenue: AMTI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMTI's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Applied Molecular Transport performed over the past 5 years?

-61.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AMTI is currently unprofitable.

Growing Profit Margin: AMTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AMTI's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: AMTI has a negative Return on Equity (-47.55%), as it is currently unprofitable.


Financial Health

How is Applied Molecular Transport's financial position?


Financial Position Analysis

Short Term Liabilities: AMTI's short term assets ($187.7M) exceed its short term liabilities ($9.7M).

Long Term Liabilities: AMTI's short term assets ($187.7M) exceed its long term liabilities ($9.8M).


Debt to Equity History and Analysis

Debt Level: AMTI is debt free.

Reducing Debt: AMTI has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AMTI has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 40.7% each year.


Dividend

What is Applied Molecular Transport current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Tahir Mahmood (46 yo)

5yrs

Tenure

US$621,009

Compensation

Dr. Tahir Mahmood, Ph D., co-founded Applied Molecular Transport Limited Liability Company in September 2010 and serves as its Chief Business Officer. He is Co-Founder, Chief Executive Officer, and Directo...


CEO Compensation Analysis

Compensation vs Market: Tahir's total compensation ($USD621.01K) is below average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Tahir's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AMTI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: AMTI's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AMTI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

Applied Molecular Transport Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Applied Molecular Transport Inc.
  • Ticker: AMTI
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$628.535m
  • Shares outstanding: 38.49m
  • Website: https://www.appliedmt.com

Number of Employees


Location

  • Applied Molecular Transport Inc.
  • 1 Tower Place
  • Suite 850
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:01
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.